Kinnate Biopharma Inc.
NASDAQ:KNTE
2.65 (USD) • At close April 2, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.799 | 0.604 | 0.123 | 0.083 | 0 | 0 |
| Gross Profit
| -0.799 | -0.604 | -0.123 | -0.083 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 90.767 | 88.15 | 67.166 | 29.237 | 8.955 | 5.675 |
| General & Administrative Expenses
| 0 | 30.371 | 22.945 | 6.764 | 3.057 | 1.955 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 27.442 | 30.371 | 22.945 | 6.764 | 3.057 | 1.955 |
| Other Expenses
| 0 | 2.25 | 0.348 | -0.005 | 0 | 0 |
| Operating Expenses
| 118.209 | 118.521 | 90.111 | 36.001 | 12.012 | 7.63 |
| Operating Income
| -119.008 | -118.521 | -90.111 | -36.001 | -12.012 | -7.63 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 6.359 | 2.25 | 0.348 | 0.24 | 0.043 | 0 |
| Income Before Tax
| -112.649 | -116.271 | -89.763 | -35.761 | -11.969 | -7.63 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -2.25 | -0.348 | -0.328 | -0.043 | 0 |
| Net Income
| -112.649 | -114.021 | -89.415 | -35.433 | -11.926 | -7.63 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| EPS Diluted
| -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| EBITDA
| -118.209 | -117.917 | -89.988 | -36.001 | -12.012 | -7.63 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |